Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos*

BACKGROUND: Extended-release (ER) paliperidone is an innovative atypical antipsychotic that allows minimal peak-to-through fluctuations with once-daily dosing.OBJECTIVE: To evaluate effectiveness, safety and tolerability of flexible, once-daily doses of paliperidone ER (3-12 mg/day) in patients with...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2012
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
spa
OAI Identifier:
oai:repository.urosario.edu.co:10336/24726
Acceso en línea:
https://doi.org/10.1016/s0034-7450(14)60009-3
https://repository.urosario.edu.co/handle/10336/24726
Palabra clave:
Public Health and Health Services
Medical and Health Sciences
Rights
License
Bloqueado (Texto referencial)
id EDOCUR2_57de814d39a9e80c24b17c444ed2707e
oai_identifier_str oai:repository.urosario.edu.co:10336/24726
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 318208660098626526600693085bf-7970-423c-ba11-4a6c4f8bdae3-11faafc30-bb7f-4c2c-a97a-b939b097ec7e-19bac02ff-eb3e-4fd8-b3de-a007c6b1e0f9-1885050fe-cecd-4c85-9c61-9df89d7725a6-1a9d5cbd2-64bc-4a17-8901-33e287ea0136-1ef8b236d-a2f2-4a30-9e11-5e6f423bc327-15c7e85af-ae91-46c5-92ff-8c5ff58d316b-1e52f5a1a-2aa4-44e2-8be4-80d79f0328df-1ebd6a6e1-1340-4d08-8556-4a4157204159-12020-06-11T13:21:06Z2020-06-11T13:21:06Z2012-06BACKGROUND: Extended-release (ER) paliperidone is an innovative atypical antipsychotic that allows minimal peak-to-through fluctuations with once-daily dosing.OBJECTIVE: To evaluate effectiveness, safety and tolerability of flexible, once-daily doses of paliperidone ER (3-12 mg/day) in patients with schizophrenia from Argentina and Colombia who had previously failed treatment with other antipsychotic agents.METHODS: The authors conducted a 6-month, open-label, prospective and multicentric study. Effectiveness was assessed with Positive and Negative Syndrome Scale (PANSS) and Personal and Social Performance scale (PSP). Other measures of effectiveness, safety and tolerability, were also conducted.RESULTS: Paliperidone ER 3-12 mg/day improved Positive and Negative Syndrome Scale (PANSS) total scores (primary endpoint) from baseline to study end (p < 0,001). In the PANSS total score, the mean change from baseline (83, 9 units) to end point (53,7 units) was significant (p < 0,001). Flexible doses of paliperidone ER demonstrated a ?20% reduction in the PANSS total score (p<0.001) in almost two-thirds of patients. PSP mean change from baseline (52 units) to end point (85 units) was significant (p < 0,001). Secondary effectiveness assessments, as well as safety and tolerability measures, demonstrated favourable results throughout the study.CONCLUSIONS: Flexible doses of paliperidone ER over 6 months were effective, safe and well tolerated in patients with schizophrenia from Argentina and Colombia.application/pdfhttps://doi.org/10.1016/s0034-7450(14)60009-3https://repository.urosario.edu.co/handle/10336/24726spaRevista Colombiana de Psiquiatría356No. 2340Revista Colombiana de PsiquiatríaVol. 41Revista Colombiana de Psiquiatría, ISSN: , Vol.41, No.2 (2012-06); pp. 340-356https://app.dimensions.ai/details/publication/pub.1007062233Bloqueado (Texto referencial)http://purl.org/coar/access_right/c_14cbinstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURPublic Health and Health ServicesMedical and Health SciencesEstudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos*articleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Cordoba Rojas, Rodrigo NelCano Romero, Juan FernandoArango-Dávila, César AugustoMiranda, CarlosHolguín, JorgeFernández, DaríoMárquez, MiguelLupo, ChristianGargoloff, PedroPetracca, GustavoLucchetti, César10336/24726oai:repository.urosario.edu.co:10336/247262021-06-03 00:50:33.511https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos*
title Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos*
spellingShingle Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos*
Public Health and Health Services
Medical and Health Sciences
title_short Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos*
title_full Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos*
title_fullStr Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos*
title_full_unstemmed Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos*
title_sort Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos*
dc.subject.keyword.spa.fl_str_mv Public Health and Health Services
Medical and Health Sciences
topic Public Health and Health Services
Medical and Health Sciences
description BACKGROUND: Extended-release (ER) paliperidone is an innovative atypical antipsychotic that allows minimal peak-to-through fluctuations with once-daily dosing.OBJECTIVE: To evaluate effectiveness, safety and tolerability of flexible, once-daily doses of paliperidone ER (3-12 mg/day) in patients with schizophrenia from Argentina and Colombia who had previously failed treatment with other antipsychotic agents.METHODS: The authors conducted a 6-month, open-label, prospective and multicentric study. Effectiveness was assessed with Positive and Negative Syndrome Scale (PANSS) and Personal and Social Performance scale (PSP). Other measures of effectiveness, safety and tolerability, were also conducted.RESULTS: Paliperidone ER 3-12 mg/day improved Positive and Negative Syndrome Scale (PANSS) total scores (primary endpoint) from baseline to study end (p < 0,001). In the PANSS total score, the mean change from baseline (83, 9 units) to end point (53,7 units) was significant (p < 0,001). Flexible doses of paliperidone ER demonstrated a ?20% reduction in the PANSS total score (p<0.001) in almost two-thirds of patients. PSP mean change from baseline (52 units) to end point (85 units) was significant (p < 0,001). Secondary effectiveness assessments, as well as safety and tolerability measures, demonstrated favourable results throughout the study.CONCLUSIONS: Flexible doses of paliperidone ER over 6 months were effective, safe and well tolerated in patients with schizophrenia from Argentina and Colombia.
publishDate 2012
dc.date.created.spa.fl_str_mv 2012-06
dc.date.accessioned.none.fl_str_mv 2020-06-11T13:21:06Z
dc.date.available.none.fl_str_mv 2020-06-11T13:21:06Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/s0034-7450(14)60009-3
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/24726
url https://doi.org/10.1016/s0034-7450(14)60009-3
https://repository.urosario.edu.co/handle/10336/24726
dc.language.iso.none.fl_str_mv spa
language spa
dc.relation.citationEndPage.none.fl_str_mv 356
dc.relation.citationIssue.none.fl_str_mv No. 2
dc.relation.citationStartPage.none.fl_str_mv 340
dc.relation.citationTitle.none.fl_str_mv Revista Colombiana de Psiquiatría
dc.relation.citationVolume.none.fl_str_mv Vol. 41
dc.relation.ispartof.spa.fl_str_mv Revista Colombiana de Psiquiatría, ISSN: , Vol.41, No.2 (2012-06); pp. 340-356
dc.relation.uri.spa.fl_str_mv https://app.dimensions.ai/details/publication/pub.1007062233
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_14cb
dc.rights.acceso.spa.fl_str_mv Bloqueado (Texto referencial)
rights_invalid_str_mv Bloqueado (Texto referencial)
http://purl.org/coar/access_right/c_14cb
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Revista Colombiana de Psiquiatría
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1808390856276705280